Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.
FOCUS 1 and 2 trials: Two Phase III, randomised, double-blind, multinational, multicentre, non-inferiority trials comparing Zinforo (600 mg IV every 12 hours, adjusted for moderate renal impairment) vs ceftriaxone (1 g IV every 24 hours)2
Clinical cure rates: FOCUS 1 and 2||
||The lower limit of the 95% CI was above –10%, which met the predefined criteria for non-inferiority.7 Zinforo was well tolerated with a safety profile similar to that of ceftriaxone.7
‡Zinforo may be associated with early clinical response, based on clinical stability and symptom improvement criteria. Early clinical response does not predict final clinical outcome for Zinforo.
*CrCL 31–50 mL/min.2
† Shown not to be statistically significant.3
§ Bacteraemia was present in 4% of patients when baseline medical characteristics were assessed.2
**Zinforo is not active against Pseudomonas aeruginosa. Like other cephalosporins, Zinforo is not active against ESBL-producing strains. In vitro activity does not always correlate with clinical efficacy.1
Zinforo 600 mg powder for concentrate for solution for infusion
Access data on the tolerability profile of Zinforo as established in key Phase III clinical trials
** This is an optional area where footnotes can live.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020